**Equity Swap Contract**

This contract is an equity swap agreement between Party A and Party B, entered into on September 24, 2001. The trade is identified by the global reference "33f59567" and the external reference "party1".

**Trade Details**

* Trade Date: September 24, 2001
* Effective Date: October 5, 2001
* Termination Date: October 5, 2033
* Mandatory Early Termination Date: November 3, 2001
* Notional Amount: USD 10,000,000
* Calculation Agent: Party A (unless stated otherwise in ISDA)
* Governing Law: English
* Documentation: ISDA

**Party Details**

* Party A: Party A is identified by the global reference "33f59567" and the external reference "party1".
* Party B: Party B is identified by the global reference "33f59568" and the external reference "party2".

**Contractual Terms**

* The swap is a total return basic performance equity swap, with the underlying security being the equity of Shire Pharmaceuticals Group - American Depositary Receipts.
* The swap has a quarterly payment schedule, with payments made on the 7th of October, January, April, and July of each year.
* The payment dates are subject to adjustment in accordance with the following business day convention: "FOLLOWING".
* The day count fraction is ACT/360.
* The swap has a reset date, which is the calculation period start date.
* The swap has a valuation date, which is the final valuation date.
* The swap has a settlement currency, which is USD.
* The swap has a settlement type, which is cash.

**Pricing Variables**

* The floating rate is USD SOFR-COMPOUND.
* The fixed rate is 4.427% per annum.

**Risk Disclosure**

* The swap carries significant risks, including but not limited to, foreign exchange risk, price risk, liquidity risk, and credit risk.
* Party B should consult their own financial, legal, accounting, and tax advisors about the risks associated with this transaction.

**Scenario Analysis**

* The following scenario analysis is provided for illustrative purposes only:
	+ Scenario 1: USD SOFR-COMPOUND remains unchanged over the tenor of the trade.
	+ Scenario 2: USD SOFR-COMPOUND increases over the tenor of the trade.
	+ Scenario 3: USD SOFR-COMPOUND decreases over the tenor of the trade.

**Mark to Market (MTM) Sensitivity Analysis**

* The following MTM analysis is provided for illustrative purposes only:
	+ Parallel shift in USD SOFR-COMPOUND curve:
		- 500 bps up: -3,969,875
		- 100 bps up: -796,597
		- 50 bps up: -398,415
		- 10 bps up: -79,698
		- 0: 0
		- 10 bps down: 79,712

**Level of Pricing Variables and Impact of Variables on Pricing**

* The market level of primary market variables used in determining the price of the transaction is as follows:
	+ USD 10 year SOFR-COMPOUND Rate: 4.427%
* The primary market variables used for determining the mark-to-market value along with their directional impact are listed below for information purposes only and is subject to change.

**Representations**

* Each party represents to the other party on the date on which it enters into this transaction that:
	+ It is acting for its own account and has made its own independent decisions to enter into this transaction.
	+ It is capable of assessing the merits of and understanding the terms, conditions, and risks of this transaction.
	+ The other party is not acting as a fiduciary for, or an adviser to it in respect of this transaction.
	+ This transaction is subject at all times to the applicable laws, including but not limited to the Reserve Bank of India and the Foreign Exchange Management Act, 1999, rules, regulations, and guidelines issued thereunder.

**Acceptance and Agreement**

* This contract is accepted and agreed upon by Party B on [date].